Renovorx pre-clinical results supporting tamp™ as a targeted locoregional drug delivery platform to receive award at sir 2025 annual scientific meeting

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared drug-delivery device, is proud to announce that a publication supporting the company's proprietary trans-arterial micro-perfusion (tamp) therapy platform for targeted locoregional drug delivery will be recognized in the journal of vascular and interventional radiology (.
RNXT Ratings Summary
RNXT Quant Ranking